25 June 2022>: Clinical Research
Serum TP53 Protein Level as a Sensitive Biomarker for the Diagnosis of Myocardial Damage in Children
Xianglin Zeng EF* , Chunwang Lin AEG** , Yanna Sun BD* , Jianping Zhang CFDOI: 10.12659/MSM.936248
Med Sci Monit 2022; 28:e936248
Table 3 Receiver operating characteristic analysis determining viability of plasma TP53 levels for differentiating patients with myocardial damage*.
TP53 | NT-proBNP | cTnI | CK-MB | |
---|---|---|---|---|
Subjects, n | 50 | 50 | 50 | 50 |
Optimal cut-off value | 12.00 ng/L | 500.00 ng/L | 0.16 μg/L | 27.00 IU/L |
AUC | 0.89 (0.81–0.95) | 0.83 (0.77–0.91) | 0.92 (0.84–0.97) | 0.85 (0.78–0.93) |
Sensitivity | 0.93 (0.88–0.98) | 0.91 (0.88–0.94) | 0.95 (0.92–0.98) | 0.94 (0.91–0.97) |
Specificity | 0.91 (0.88–0.94) | 0.81 (0.61–0.88) | 0.97 (0.95–0.99) | 0.88 (0.85–0.91) |
Positive likelihood ratio | 20.8 | 13.2 | 24.6 | 15.6 |
* Reported as value (95% CI), unless otherwise noted. |